| Name | Title | Contact Details |
|---|
About Calvary Center: Residential/Inpatient/Full Medical Detox/IOP/PHP Treatment for Alcohol, Drugs and Problem Gambling Calvary Addiction Recovery Centers treatment program is for men and women, 18 years and older, who are struggling with substa...
Nestle Health Science is pioneering a new field where nutrition becomes therapy. We are changing the course of health through research and innovation, and nutritional therapies. Visit the site to learn more.
Symphogen, Inc. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CardioRisk is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density. Tricida has successfully completed all of the clinical trials that it planned to complete prior to submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), including a successful 135-subject, Phase 1/2 clinical trial (TRCA-101), a successful 217-subject, pivotal Phase 3 clinical trial (TRCA-301), and a successful 196-subject, Phase 3 extension trial (TRCA-301E). We plan to submit an NDA, in the second half of 2019, seeking approval of TRC101 through the FDA`s Accelerated Approval Program. Tricida was founded in August 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases. Tricida`s shared culture of teamwork, camaraderie and empowerment is evident in the dedication and focus our team demonstrates, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD, and bringing critically needed new therapies to patients.